# Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Canonical URL: https://biopharmsignal.com/news/NEPH/nephros-launches-new-pfas-filter-for-point-of-use-protection-of-potable-water-1b863160
Ticker: NEPH
Company: Nephros
Source: Nephros
Published: 2025-10-08 13:00 EST
## Summary

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the lau...

## Article Body
Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros’ portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention.

PFAS, sometimes referred to as “forever chemicals,” are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health.

“Unlike most filters that only address PFOA and PFOS, the Nephros 19-Series PFAS Filter has been independently tested to reduce Total PFAS, offering protection against a much broader spectrum of contaminants,” said Robert Banks, President & CEO of Nephros. “By combining PFAS reduction with protection against lead, asbestos, and other hazards, we believe the 19-Series PFAS Filter helps set a new benchmark in support of safer, more reliable drinking water.”

Key Features of the Nephros 19-Series PFAS Filter

Independently tested to NSF Standards 42 and 53

Validated reduction of Total PFAS, including PFOA and PFOS

Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor

3,145-gallon capacity with a 1.63 GPM flow rate

Provides long-term protection against persistent, health-threatening waterborne contaminants

The Nephros 19-Series PFAS filter is ideal for industries and facilities where water safety is critical, including healthcare, daycares, education, foodservice, and manufacturing. For more information, including performance data, please visit the Nephros 19-Series Filter product page on our website.

About Nephros Nephros is a leading provider of filtration products to medical and commercial markets, offering a wide range of solutions that deliver superior filtration performance. With advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.

For more information about Nephros, visit nephros.com

Forward-Looking Statements This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected benefits of the 19-Series PFAS Filter and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ dependence on third-party manufacturers, distributors and researchers, changes in business and competitive conditions and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

Investor Relations Contacts: Kirin Smith, President PCG Advisory, Inc. (646) 823-8656 ksmith@pcgadvisory.com

Robert Banks, CEO Nephros, Inc. (201) 343-5202 robert.banks@nephros.com

Judy Krandel, CFO Nephros, Inc. (201) 343-5202 judy.krandel@nephros.com
## Recent Company News
- 2026-07-20 11:00 EST — [Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET](https://biopharmsignal.com/news/NEPH/nephros-to-participate-in-the-health-wellness-longevity-virtual-conference-prese-04bc108f) — Source: Nephros
- 2026-07-06 11:00 EST — [Nephros Announces Inclusion in the Russell Microcap® Index](https://biopharmsignal.com/news/NEPH/nephros-announces-inclusion-in-the-russell-microcap-index-8f384e42) — Source: Nephros
- 2026-06-18 11:00 EST — [Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”](https://biopharmsignal.com/news/NEPH/nephros-to-host-virtual-investor-event-beyond-filtration-the-nephros-model-in-ac-6be1cdda) — Source: Nephros
- 2026-06-16 11:00 EST — [Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water](https://biopharmsignal.com/news/NEPH/nephros-positions-ultrafiltration-technology-as-a-solution-to-emerging-microplas-60dc48d7) — Source: Nephros
- 2026-05-07 20:05 EST — [Nephros Announces Financial Results for Quarter Ended March 31, 2026](https://biopharmsignal.com/news/NEPH/nephros-announces-financial-results-for-quarter-ended-march-31-2026-6679efc9) — Source: Nephros
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)